Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Stock Information for Ovid Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.